Del. chains accept Medicaid rates, but consultant R.Ph.s sue

The therapy is currently under FDA review and has a PDUFA action date of May 22, 2025.

President of 3 Axis Advisors and CEO of 46brooklyn Research joins Drug Topics to discuss nuances surrounding pharmacy benefit managers and the way they are perceived in the public eye.

Guselkumab is the first and only IL-23 inhibitor to demonstrate robust data as a fully subcutaneous regimen.

In this episode of the podcast, Natalie DiPietro Mager, PharmD, PhD, sits down with Jasmine Cutler, PharmD, CPh.

A phase 2 study found 95% of patients achieved a sustained virologic response at 12 weeks regardless of treatment adherence.

Selarsdi is interchangeable for all indications of ustekinumab, including treatment of psoriatic arthritis, plaque psoriasis, Crohn disease, and ulcerative colitis.